Ikarian Capital, LLC Allakos Inc. Transaction History

Ikarian Capital, LLC

$714 Million
Q1 2025

A detailed history of Ikarian Capital, LLC transactions in Allakos Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 1,171,950 shares of ALLK stock, worth $386,743. This represents 0.04% of its overall portfolio holdings.

Number of Shares

1,171,950

Previous 971,950 20.58%

Holding current value

$386,743

Previous $1.18 Million 77.13%

% of portfolio

0.04%

Previous 0.19%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.23 - $1.24 $46,000 - $248,000	200,000 Added 20.58%	1,171,950 $269,000
Q4 2024 Feb 14, 2025	SELL	$0.62 - $1.5 $449 - $1,087	-725 Reduced 0.07%	971,950 $1.18 Million
Q2 2024 Aug 14, 2024	BUY	$1.0 - $1.45 $40,000 - $58,000	40,000 Added 4.29%	972,675 $972,000
Q1 2024 May 15, 2024	BUY	$1.02 - $3.23 $709,531 - $2.25 Million	695,619 Added 293.44%	932,675 $1.18 Million
Q4 2023 Feb 14, 2024	SELL	$1.72 - $3.18 $946,000 - $1.75 Million	-550,000 Reduced 69.88%	237,056 $647,000
Q3 2023 Nov 14, 2023	BUY	$2.13 - $5.55 $31,873 - $83,050	14,964 Added 1.94%	787,056 $1.79 Million
Q2 2023 Aug 14, 2023	BUY	$3.6 - $5.25 $2.78 Million - $4.05 Million	772,092 New	772,092 $3.37 Million
Q3 2021 Nov 15, 2021	SELL	$76.53 - $110.43 $13,316 - $19,214	-174 Reduced 0.55%	31,526 $3.34 Million
Q1 2021 May 17, 2021	BUY	$109.73 - $153.66 $3.48 Million - $4.87 Million	31,700 New	31,700 $3.64 Million
Q3 2020 Nov 16, 2020	SELL	$66.43 - $90.99 $2.83 Million - $3.87 Million	-42,536 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$44.04 - $80.69 $1.87 Million - $3.43 Million	42,536 New	42,536 $3.06 Million

Others Institutions Holding ALLK

# of Institutions

Shares Held

61M

Call Options Held

71.5K

Put Options Held

19.8K

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $28M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.

Account

Ikarian Capital, LLC Allakos Inc. Transaction History